Eli Lilly (NYSE: LLY) and (NASDAQ: BIIB) are both keen to compete in the market for Alzheimer's disease therapies. Biogen's prior attempt at an Alzheimer's medicine to hit the market was a train wreck, but its latest drug seems to be avoiding a repeat.

Meanwhile, Eli Lilly has yet to submit its candidate for regulatory review. And while the recently released phase 3 clinical trial data for Lilly's candidate looks promising, it too has a record of swinging and missing.

So is the high likelihood of an Alzheimer's market showdown going to make or break one of these two titans? It isn't likely. In fact, both could flourish -- but one might flourish more than the other. Here's why.

Continue reading

Source Fool.com